24248-21-3

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3-(2,6-DICHLORO-PHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXYLATE is used as a key intermediate compound for the synthesis of isoxazole carboxamides. These carboxamides are known to exhibit growth hormone properties, making them valuable in the development of pharmaceuticals aimed at promoting growth and development in various medical conditions.
Used in Agricultural Industry:
In the agricultural industry, ETHYL 3-(2,6-DICHLORO-PHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXYLATE can be used as a precursor for the development of growth hormones that can enhance the growth and yield of crops. By incorporating these growth hormones into agricultural practices, farmers can potentially improve the overall productivity and sustainability of their crops.
Used in Research and Development:
ETHYL 3-(2,6-DICHLORO-PHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXYLATE is also used in research and development for the creation of new compounds with potential applications in various fields. Its unique chemical properties make it an interesting candidate for further study and experimentation, potentially leading to the discovery of new drugs, materials, or technologies.

InChI:InChI=1/C13H11Cl2NO3/c1-3-18-13(17)10-7(2)19-16-12(10)11-8(14)5-4-6-9(11)15/h4-6H,3H2,1-2H3

Upstream product

• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 141-97-9 ethyl acetoacetate 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 105-45-3 acetoacetic acid methyl ester 
• 83-38-5 2,6-dichlorobenzaldehyde 

Downstream Products

• 3919-76-4 3-(2,6-dichloro-phenyl)-5-methyl-isoxazole-4-carboxylic acid 
• 543686-34-6 3-(2,6-dichlorophenyl)-N-[4-(diethylamino)phenyl]-5-methylisoxazole-4-carboxamide 
• 848186-99-2 3-(2,6-dichlorophenyl)-N-[4-(diethylamino)-2-methoxyphenyl]-5-methylisoxazole-4-carboxamide 
• 1268246-42-9 C₁₄H₁₁Cl₂NO₄ 
• 1268246-43-0 C₁₄H₁₃Cl₂NO₄ 
• 1268246-44-1 C₁₉H₂₁Cl₂NO₅ 
• 1268246-45-2 C₁₇H₁₉Cl₂NO₄ 

Relevant academic research and scientific papers

ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.

NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

The first low μM SecA inhibitors

SecA ATPase is a critical member of the Sec family, which is important in the translocation of membrane and secreted polypeptides/proteins in bacteria. Small molecule inhibitors can be very useful research tools as well as leads for future antimicrobial agent development. Based on previous virtual screening work, we optimized the structures of two hit compounds and obtained SecA ATPase inhibitors with IC50 in the single digit micromolar range. These represent the first low micromolar synthetic inhibitors of bacterial SecA and will be very useful for mechanistic studies.

Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists

A series of isoxazole carboxamide derivatives has been developed as potent ghrelin receptor antagonists. The synthesis and structure-activity relationship (SAR) are described.

Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists

Novel isoxazole carboxamides have been identified as growth hormone secretagogue receptor (GHS-R) antagonists. Substituent modification off the 5-position of the isoxazole ring led to analogues with potent binding affinity and functional antagonism of GHS-R. A potent analogue (32) with high aqueous solubility and good GPCR selectivity was also identified as a potential pharmacological tool for in vivo studies.